<DOC>
	<DOC>NCT01123070</DOC>
	<brief_summary>The purpose of this study is to determine the safety and pharmacology of TL011 in patients with severe rheumatoid arthritis.</brief_summary>
	<brief_title>TL011 in Severe, Active Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult subjects Rheumatoid arthritis as defined by the 1987 ACR Classification Severe active seropositive disease Inadequate response or intolerance to other DMARDs Treatment with MTX Rheumatic autoimmune disease other than RA Active infection Known immunodeficiency syndrome Positive Hepatitis B surface antigen or antibodies to Hepatitis C History of cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>